Interestingly, TMZ+low-dose CuCl2 co-treatment enhances the sensitivity of glioma cells to TMZ, leading to a reduction in cell proliferation and migration, and ultimately causing the accumulation of the copper death marker protein DLAT in the mitochondria, triggering copper-induced cell death in glioma cells. The gene discussed is DLAT; the disease is central nervous system cancer.